Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease
Status: | Enrolling by invitation |
---|---|
Conditions: | Gastrointestinal, Hepatitis |
Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - 74 |
Updated: | 2/21/2019 |
Start Date: | January 25, 2019 |
End Date: | October 2019 |
This study evaluates the effect of erythropoietin on the number and function of regulatory T
cells in adults with autoimmune hepatitis. Participants will receive a single dose of
erythropoietin, and then the investigators will collect blood at different time points for
analysis of regulatory T cell number and function.
cells in adults with autoimmune hepatitis. Participants will receive a single dose of
erythropoietin, and then the investigators will collect blood at different time points for
analysis of regulatory T cell number and function.
There is data from the laboratory that erythropoietin helps stimulate regulatory T cells, a
type of immune cell which is thought to combat autoimmunity, but this study will look at
whether it does the same thing in adults with autoimmune hepatitis.
type of immune cell which is thought to combat autoimmunity, but this study will look at
whether it does the same thing in adults with autoimmune hepatitis.
Inclusion Criteria:
- Diagnosis of autoimmune liver diseases (autoimmune hepatitis, autoimmune
cholangiopathy, or primary biliary cirrhosis or primary sclerosing cholangitis with
hepatic autoimmune liver disease or overlap syndrome) confirmed on liver biopsy
- Use of immunosuppressive therapy (prednisone, azathioprine, 6-mercaptopurine,
mycophenolate mofetil) for the treatment of the autoimmune liver disease
- Stable immunosuppression regimen at least 6 months prior to enrollment
- Ability to provide verbal and written informed consent
Exclusion Criteria:
- Diagnosis of decompensated cirrhosis (defined by presence of ascites, varices,
encephalopathy)
- Hemoglobin above average normal value (15.7 g/dL in men, 13.8 g/dL in women)
- Alanine aminotransferase greater than 2 times upper limit of normal (33 IU/L in men
and 25 IU/L in women)
- Uncontrolled hypertension with systolic blood pressure greater than or equal to 160 or
diastolic blood pressure greater than or equal to 100
- End-stage renal disease on hemodialysis
- History of venous thromboembolism including deep vein thromboses or pulmonary emboli
- History of stroke
- History of heart failure
- History of seizure disorder
- History of significant cardiovascular disease including a history of myocardial
infarction
- Active malignancy (untreated or undergoing therapy)
- History of pure red cell aplasia
- History of intolerance or allergy to erythropoietin
- Known hypersensitivity to mammalian cell-derived products
- Known hypersensitivity to human albumin
- Presence of vascular access
- Prior recipient of erythropoietin within 12 weeks of the study
- Patient unable to provide consent including infants, children, teenagers, prisoners,
cognitively impaired adults
- Non-English speaking
- Pregnancy
We found this trial at
2
sites
Click here to add this to my saved trials